28410

STUDY OF THE EFFECT OF DIBENZAZEPINE IN RENAL INJURY INDUCED BY CISPLATIN IN RATS

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

-

Abstract

Indeed, cisplatin is a standard anti-cancer agent that is used in the management of different types of solid tumors. Unfortunately, cisplatin significantly accumulates in renal proximal tubular cells where nephrotoxicity is the main side effect limiting its clinical use. The present study was conducted to explore the possible nephroprotective effect of dibenzazepine against cisplatin-induced renal injury in rats. Rats received pre-treatment with three different doses of dibenzazepine for one week before giving cisplatin at a one single dose (7 mg/kg) intraperitoneally. The renal injury was determined by measuring nephrotoxicity markers as well as histopathological investigation.  Dibenzazepine attenuated the elevation in blood urea nitrogen and serum creatinine levels. Moreover, the nephroprotective effect of dibenzazepine was further confirmed histopathologically. In conclusion, these findings show that dibenzazepine provides protection against renal injury induced by cisplatin.

DOI

10.21608/ajps.2017.28410

Authors

First Name

Rana

Last Name

Abd El-Rhman

MiddleName

-

Affiliation

Department of Pharmacology, The National Organization for Drug Control and Research, Cairo, Egypt

Email

-

City

-

Orcid

-

Volume

55

Article Issue

1

Related Issue

5065

Issue Date

2017-03-01

Receive Date

2019-03-06

Publish Date

2017-03-01

Page Start

109

Page End

117

Print ISSN

1110-1644

Online ISSN

2535-1958

Link

https://ajps.journals.ekb.eg/article_28410.html

Detail API

https://ajps.journals.ekb.eg/service?article_code=28410

Order

8

Type

Original Article

Type Code

518

Publication Type

Journal

Publication Title

Al-Azhar Journal of Pharmaceutical Sciences

Publication Link

https://ajps.journals.ekb.eg/

MainTitle

STUDY OF THE EFFECT OF DIBENZAZEPINE IN RENAL INJURY INDUCED BY CISPLATIN IN RATS

Details

Type

Article

Created At

22 Jan 2023